^
    16h
    Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Maastricht University Medical Center
    New P2 trial
    |
    Avastin (bevacizumab) • Trodelvy (sacituzumab govitecan-hziy)
    6d
    Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (clinicaltrials.gov)
    P3, N=1530, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Combination therapy • Surgery
    |
    Keytruda (pembrolizumab) • capecitabine • sacituzumab tirumotecan (MK-2870)
    7d
    SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov)
    P3, N=440, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P3 trial
    |
    paclitaxel • doxorubicin hydrochloride • topotecan • SHR-A1921
    11d
    Antibody-drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis. (PubMed, Front Oncol)
    Since the FDA's approval of Enfortumab Vedotin and Sacituzumab Govitecan, the therapeutic landscape has expanded, heralding a shift towards antibody-drug conjugates as potential first-line therapies. These findings affirm the increasing significance of antibody-drug conjugates in urothelial carcinoma treatment, transitioning them from posterior-line to frontline therapies. Future research is poised to focus on new therapeutic targets, combination therapy optimization, treatment personalization, exploration of double antibody-coupled drugs, and strategies to overcome drug resistance.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • EPCAM (Epithelial cell adhesion molecule)
    |
    PD-L1 expression
    |
    Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)
    12d
    Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov)
    P2, N=531, Recruiting, AstraZeneca | Trial completion date: Mar 2025 --> Aug 2026 | Trial primary completion date: Mar 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • Combination therapy • Pan tumor • Metastases
    |
    Avastin (bevacizumab) • carboplatin • Imfinzi (durvalumab) • 5-fluorouracil • capecitabine • leucovorin calcium • datopotamab deruxtecan (DS-1062a) • saruparib (AZD5305) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    12d
    A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=378, Not yet recruiting, Shanghai Escugen Biotechnology Co., Ltd
    New P3 trial • Metastases
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • ESG401
    14d
    A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers. (PubMed, NPJ Precis Oncol)
    Moreover, compared to sacituzumab govitecan, hIMB1636-LDP-AE showed more potent antitumor activity and significantly lower myelotoxicity in tumors with moderate Trop2 expression. This study fully revealed the potent antitumor efficacy of hIMB1636-LDP-AE, and also provided a new preparation method for LDM-based ADC, as well as a promising candidate for breast cancer and lung cancer therapeutics.
    Journal
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    TROP2 expression • TROP2 positive
    |
    Trodelvy (sacituzumab govitecan-hziy)
    14d
    Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. (PubMed, J Clin Oncol)
    In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.
    P1 data • Journal • Pan tumor • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    datopotamab deruxtecan (DS-1062a)
    14d
    Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape. (PubMed, Curr Oncol Rep)
    ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape. ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.
    Review • Journal
    |
    STEAP1 (STEAP Family Member 1)
    |
    Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)
    14d
    Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation. (PubMed, Ann Oncol)
    In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 (datopotamab deruxtecan and sacituzumab govitecan [SG]) and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development. In breast cancer, several agents are already approved and widely used, including trastuzumab emtansine, T-DXd and SG, and multiple late-stage trials are ongoing...The ETOP IBCSG Partners Foundation are driving strong collaborations in this field and promoting the generation/sharing of databases, repositories and registries to enable greater access data. This will allow the most important research questions to be identified and prioritised, which will ultimately accelerate progress and help to improve patient outcomes.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • HER-2 mutation
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • patritumab deruxtecan (U3-1402) • Trodelvy (sacituzumab govitecan-hziy) • datopotamab deruxtecan (DS-1062a) • telisotuzumab vedotin (ABBV-399)
    18d
    Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Henry Ford Health System | Initiation date: Feb 2024 --> Jun 2024
    Trial initiation date • Combination therapy • Metastases
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    capecitabine • Trodelvy (sacituzumab govitecan-hziy)
    19d
    Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=56, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Trodelvy (sacituzumab govitecan-hziy)
    20d
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without MK- 2870 in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (clinicaltrials.gov)
    P3, N=780, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • sacituzumab tirumotecan (MK-2870)
    21d
    Tropion-Lung08: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=740, Recruiting, Daiichi Sankyo | Trial completion date: Jun 2026 --> Apr 2028 | Trial primary completion date: Jun 2026 --> Feb 2028
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • datopotamab deruxtecan (DS-1062a)
    21d
    Saci-IO TNBC: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC (clinicaltrials.gov)
    P2, N=110, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Apr 2027 --> Apr 2029 | Trial primary completion date: Apr 2024 --> Apr 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • PD-L1 negative • PGR expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP142) Assay
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    21d
    A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors (clinicaltrials.gov)
    P2, N=18, Recruiting, Georgetown University | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Trodelvy (sacituzumab govitecan-hziy)
    27d
    Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. (PubMed, Breast Cancer)
    The observed response rate and safety of SG are consistent with the results of the ASCENT trial, with efficacy observed in patients with brain metastases, but observed PFS and OS are numerically shorter.
    Journal • BRCA Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Trodelvy (sacituzumab govitecan-hziy)
    27d
    Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis. (PubMed, Front Oncol)
    The results of this real-world analysis showed that both safety and efficacy of sacituzumab govitecan in mTNBC patients are consistent with that previously reported in regulatory trials. The use of premedication and supportive measures was associated with a satisfactory toxicity profile.
    Journal • Real-world evidence • Real-world • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER expression
    |
    Trodelvy (sacituzumab govitecan-hziy)
    27d
    A Study to Evaluate MK-2870 in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Metastases
    |
    paclitaxel • docetaxel • irinotecan • Lonsurf (trifluridine/tipiracil) • sacituzumab tirumotecan (MK-2870)
    28d
    TROPION-Lung10: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=675, Not yet recruiting, AstraZeneca
    New P3 trial • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    TROP2 positive
    |
    Keytruda (pembrolizumab) • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936)
    28d
    Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Fudan University
    New trial • Real-world evidence • Real-world effectiveness • Real-world • Metastases
    |
    Trodelvy (sacituzumab govitecan-hziy)
    28d
    Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) (clinicaltrials.gov)
    P2, N=137, Active, not recruiting, Daiichi Sankyo | Trial completion date: May 2026 --> Dec 2024
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • EGFR mutation • EGFR overexpression • MET exon 14 mutation
    |
    datopotamab deruxtecan (DS-1062a)
    1m
    Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. (PubMed, Clin Pharmacokinet)
    These analyses support the approved SG dosing regimen of 10 mg/kg as intravenous infusion on days 1 and 8 of 21-day cycles and did not identify a need for dose adjustment based on evaluated covariates or disease characteristics.
    PK/PD data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HR positive • HER-2 negative • UGT1A1*1*1
    |
    Trodelvy (sacituzumab govitecan-hziy)
    1m
    TROPION-Lung14: Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=582, Not yet recruiting, AstraZeneca
    New P3 trial • Metastases
    |
    Tagrisso (osimertinib) • datopotamab deruxtecan (DS-1062a)
    1m
    A Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (clinicaltrials.gov)
    P3, N=1200, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • sacituzumab tirumotecan (MK-2870)
    1m
    Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) (clinicaltrials.gov)
    P2, N=137, Active, not recruiting, Daiichi Sankyo | Trial completion date: May 2024 --> May 2026
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • EGFR mutation • EGFR overexpression • MET exon 14 mutation
    |
    datopotamab deruxtecan (DS-1062a)
    1m
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Bio-Thera Solutions
    New P1/2 trial
    |
    BAT8008 • BAT1308
    1m
    Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. (clinicaltrials.gov)
    P1/2, N=75, Recruiting, Massachusetts General Hospital | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER negative • PGR negative
    |
    Talzenna (talazoparib) • Trodelvy (sacituzumab govitecan-hziy)
    1m
    Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer. (PubMed, Biomedicines)
    Historically, trastuzumab emtansine (T-DM1) has been the most commonly used ADC for both early and metastatic HER2-positive disease. Considering the recent evidence related to trastuzumab deruxtecan (T-DXd), it is expected to assume the role of the main ADC in our clinical practice. Herein, we report a retrospective analysis of the sequence of different ADCs relying on available published data from clinical trials.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy)
    1m
    ASCENT-J02: Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=143, Recruiting, Gilead Sciences | Trial primary completion date: Apr 2025 --> May 2026
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Trodelvy (sacituzumab govitecan-hziy)
    1m
    Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy (clinicaltrials.gov)
    P2, N=120, Suspended, Vanderbilt-Ingram Cancer Center | Recruiting --> Suspended
    Trial suspension • Circulating tumor DNA • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PD-L1 negative
    |
    Trodelvy (sacituzumab govitecan-hziy)
    1m
    SG-ESCC: Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, National Taiwan University Hospital
    New P2 trial • Metastases
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Trodelvy (sacituzumab govitecan-hziy)
    2ms
    Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. (PubMed, Cancer Treat Rev)
    This article summarizes the incidence of AESIs among patients with HR+/HER2- BC, TNBC, and NSCLC reported in TROPION-PanTumor01. We report our recommendations for AESI prophylaxis, early detection, and management, using experience gained from treating AESIs that occur with Dato-DXd in clinical trials.
    Review • Journal • Adverse events
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    datopotamab deruxtecan (DS-1062a)
    2ms
    A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma (clinicaltrials.gov)
    P2, N=50, Recruiting, Yale University | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial primary completion date
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Trodelvy (sacituzumab govitecan-hziy)
    2ms
    TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma. (PubMed, Pathologica)
    Different combinations of other positive biomarkers may help the choice of medical therapies. Overall, these findings have important clinical implications for targeted therapy for BUC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • NTRK (Neurotrophic receptor tyrosine kinase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 amplification • HER-2 expression • NECTIN4 expression
    2ms
    Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=56, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Initiation date: Dec 2023 --> Apr 2024
    Trial initiation date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Trodelvy (sacituzumab govitecan-hziy)
    2ms
    A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
    P2, N=88, Recruiting, Fudan University | N=66 --> 88
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive
    |
    trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • Airui'en (rezvilutamide) • SHR-A1921
    2ms
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without MK- 2870 in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (clinicaltrials.gov)
    P3, N=780, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Surgery
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • sacituzumab tirumotecan (MK-2870)
    2ms
    A Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (clinicaltrials.gov)
    P3, N=1200, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • sacituzumab tirumotecan (MK-2870)
    2ms
    Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) (clinicaltrials.gov)
    P2, N=500, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial • Metastases
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)
    2ms
    A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN) (clinicaltrials.gov)
    P2, N=40, Recruiting, Adrienne G. Waks | Initiation date: Apr 2024 --> Nov 2023
    Trial initiation date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PGR expression
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    2ms
    Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer (clinicaltrials.gov)
    P1/2, N=54, Not yet recruiting, Icahn School of Medicine at Mount Sinai | Initiation date: Sep 2023 --> Mar 2024
    Trial initiation date • Combination therapy
    |
    cisplatin • Trodelvy (sacituzumab govitecan-hziy)